302 related articles for article (PubMed ID: 29205470)
1. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
2. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
3. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
4. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced asthma in a patient with non-small-cell lung cancer.
Maeno K; Fukuda S; Oguri T; Niimi A
Ann Oncol; 2017 Nov; 28(11):2891. PubMed ID: 28945837
[No Abstract] [Full Text] [Related]
6. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
7. HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.
Yoneshima Y; Kato K; Minami H; Ikeda M; Watanabe H; Yoshimoto G; Miyamoto T; Akashi K; Nakanishi Y; Okamoto I
Cancer Sci; 2020 Sep; 111(9):3395-3396. PubMed ID: 32557883
[No Abstract] [Full Text] [Related]
8. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
9. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.
Dall'Olio FG; Sperandi F; Rihawi K; Gargiulo M; Melotti B; Brocchi S; Gelsomino F; Ardizzoni A
J Thorac Oncol; 2018 Dec; 13(12):e247-e248. PubMed ID: 30467045
[No Abstract] [Full Text] [Related]
10. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
[No Abstract] [Full Text] [Related]
11. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
[No Abstract] [Full Text] [Related]
12. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
13. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
C Guven D; Kilickap S; Guner G; Taban H; Dizdar O
J Oncol Pharm Pract; 2020 Jan; 26(1):256-258. PubMed ID: 31566114
[TBL] [Abstract][Full Text] [Related]
14. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
15. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
16. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
17. Bilateral Anterior Uveitis Associated with Nivolumab Therapy.
Karlin J; Gentzler R; Golen J
Ocul Immunol Inflamm; 2018; 26(2):283-285. PubMed ID: 27599197
[No Abstract] [Full Text] [Related]
18. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
19. Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report.
Kim YE; Kim TM; Jo SJ
J Dermatol; 2019 Dec; 46(12):e464-e466. PubMed ID: 31531885
[No Abstract] [Full Text] [Related]
20. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
[No Abstract] [Full Text] [Related]
[Next] [New Search]
